RxSight, Inc. RXST R2K
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is headquartered in Aliso Viejo, California.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Compounding revenue at 40.0% over 5 years.
- Profit CAGR of 13.9% over 5 years.
CONS
- Trading 66.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | RXST RxSight, Inc. R2K | 5.33 | - | $220.64M | - | -13.61% | -17.06% | 40.00% | 13.89% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 2.71M | 4.17M | 3.48M | 4.90M | 5.79M | 8.94M | 11.36M | 12.62M | 17.49M | 20.81M | 22.20M | 29.51M | 34.89M | - | - | 37.90M | 33.64M | 30.34M | 32.61M | 30.89M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.57M | 8.45M | 6.11M | 7.34M | 7.39M |
| Gross Profit | - | -474.00K | 720.00K | 1.12M | -812.00K | 1.34M | 3.76M | 4.79M | 5.36M | 10.37M | 12.02M | 13.73M | 20.68M | 24.25M | - | - | 28.33M | 25.19M | 24.23M | 25.26M | 23.50M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 39.00M | 39.19M | 36.41M | 36.60M | 41.33M |
| Operating Income | - | -8.81M | -8.91M | -11.13M | -13.88M | -13.11M | -16.58M | -15.79M | -15.96M | -13.10M | -13.62M | -12.51M | -10.67M | -8.33M | - | - | -10.67M | -14.00M | -12.18M | -11.34M | -17.83M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -7.38M | -10.97M | -8.95M | -8.29M | -15.04M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.00K | 5.00K | 4.00K | 5.00K | 3.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -8.17M | -11.75M | -9.81M | -9.15M | -15.88M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 18.00K | 32.00K | 10.00K | 5.00K | 6.00K |
| Net Income | -16.50M | -12.88M | 30.66M | -6.80M | -13.48M | -12.67M | -17.60M | -16.73M | -16.82M | -13.21M | -13.80M | -12.41M | -9.10M | -6.08M | - | - | -8.19M | -11.79M | -9.82M | -9.15M | -15.88M |
| Diluted EPS | - | 0.00 | 0.00 | - | -3.53 | -0.68 | -0.64 | -0.61 | -0.61 | -0.42 | -0.40 | -0.35 | -0.25 | -0.16 | - | - | -0.20 | -0.29 | -0.24 | -0.22 | -0.38 |
| R&D Expense | - | 5.08M | 5.80M | 6.64M | 6.56M | 5.38M | 6.72M | 6.19M | 6.39M | 7.21M | 7.40M | 7.10M | 8.03M | 8.29M | 8.84M | - | 10.37M | 10.22M | 9.06M | - | 9.47M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 14.68M | - | 49.01M | 89.08M | 139.93M | 134.48M |
| Cost of Revenue | - | - | 27.68M | 35.31M | 40.98M | 31.47M |
| Gross Profit | 1.71M | - | 21.33M | 53.77M | 98.94M | 103.01M |
| Operating Expenses | - | - | 84.65M | 103.85M | 135.80M | 151.20M |
| Operating Income | -35.41M | - | -63.32M | -50.09M | -36.86M | -48.19M |
| EBITDA | - | - | -57.78M | -41.20M | -23.81M | -35.59M |
| Interest Expense | - | - | 4.95M | 3.31M | 21.00K | 19.00K |
| Pretax Income | - | - | -66.75M | -48.59M | -27.41M | -38.88M |
| Tax Provision | - | - | 9.00K | 20.00K | 50.00K | 66.00K |
| Net Income | 27.57M | - | -66.76M | -48.61M | -27.45M | -38.94M |
| Diluted EPS | 0.15 | -3.57 | -2.41 | -1.41 | -0.71 | - |
| R&D Expense | 21.93M | 24.50M | 25.98M | 29.05M | 34.37M | 38.55M |
Compounded Sales Growth
| 5 Years: | 40.00% |
| 1 Year: | -18.50% |
Compounded Profit Growth
| 5 Years: | 13.89% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -65.14% |
| 6 Months: | -50.05% |
| 3 Months: | -28.74% |
| 1 Month: | -21.73% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 100.68M | - | 150.16M | 182.55M | 318.56M | 311.81M |
| Current Assets | - | - | - | 134.56M | 168.41M | 293.82M | 287.46M |
| Cash & Equivalents | - | 13.99M | - | 11.83M | 9.69M | 16.71M | 19.95M |
| Inventory | - | - | - | 14.84M | 17.42M | 22.01M | 31.56M |
| Receivables | - | - | - | 10.96M | 20.28M | 30.05M | 23.38M |
| Total Liabilities | - | 44.91M | - | 60.26M | 22.19M | 37.33M | 36.13M |
| Current Liabilities | - | 11.60M | - | 17.24M | 20.90M | 25.88M | 26.25M |
| Long Term Debt | - | 24.40M | 39.76M | 40.17M | - | - | - |
| Total Debt | - | - | - | 44.99M | 3.01M | 12.30M | 11.04M |
| Total Equity | -419.81M | -430.59M | - | 89.90M | 160.36M | 281.24M | 275.68M |
| Shares Outstanding | - | - | - | 28.27M | 36.14M | 40.43M | 41.24M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -35.20M | - | -58.85M | -41.59M | -16.95M | -15.51M |
| Investing Cash Flow | 15.59M | - | 39.95M | -22.13M | -99.31M | 16.89M |
| Financing Cash Flow | 25.24M | - | 6.33M | 61.52M | 123.32M | 1.86M |
| Capital Expenditure | -2.54M | - | -2.39M | -4.81M | -5.44M | -3.83M |
| Free Cash Flow | -37.74M | - | -61.24M | -46.41M | -22.39M | -19.34M |
| Net Change in Cash | - | - | -12.57M | -2.20M | 7.06M | 3.24M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | 11.6% | - | 43.5% | 60.4% | 70.7% | 76.6% |
| Operating Margin % | -241.3% | - | -129.2% | -56.2% | -26.3% | -35.8% |
| Net Margin % | 187.9% | - | -136.2% | -54.6% | -19.6% | -29.0% |
| ROE % | -6.4% | - | -74.3% | -30.3% | -9.8% | -14.1% |
| ROCE % | -39.8% | - | -47.6% | -31.0% | -12.6% | -16.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 7.70% | 3.19M | $16.99M |
| 2 | Artisan Partners Limited Partnership | 4.97% | 2.06M | $10.97M |
| 3 | Millennium Management Llc | 4.97% | 2.06M | $10.98M |
| 4 | Nomura Holdings Inc. | 4.83% | 2.00M | $10.66M |
| 5 | No Street GP LP | 4.83% | 2.00M | $10.66M |
| 6 | Shaw D.E. & Co., Inc. | 4.73% | 1.96M | $10.45M |
| 7 | Vanguard Capital Management LLC | 4.09% | 1.69M | $9.02M |
| 8 | Two Sigma Investments, LP | 3.14% | 1.30M | $6.93M |
| 9 | Bank of America Corporation | 2.92% | 1.21M | $6.45M |
| 10 | Healthcare of Ontario Pension Plan Trust Fund | 2.73% | 1.13M | $6.03M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RXST